$Invesco QQQ(QQQ)$ Yesterday was an interesting day for SLS.
The company filed an 8-K that further clarified the warrant situation.
On the same day, Memorial Sloan Kettering launched a major new campaign built around themes like "Treatment on a cellular level," "Hope on another level," and "Better, longer lives."
Dr. Angelos Stergiou publicly commented: "We are anxiously anticipating the REGAL data as we work together to transform the landscape of cancer care."
For those new, GPS was developed at Memorial Sloan Kettering and is currently being evaluated in the Phase 3 REGAL trial.
Meanwhile:
- The 80th event still hasn't occurred.
- REGAL remains significantly delayed.
- The warrant overhang continues to shrink.
- MSK and SELLAS keep emphasizing the same themes: hope, survival, and transforming cancer care.
The science came from MSK.
The trial is still running.
The clock is ticking.
Comments